Portal de Periódicos da CAPES

Neonatal Drug Withdrawal

2012; American Academy of Pediatrics; Volume: 129; Issue: 2 Linguagem: Inglês

10.1542/peds.2011-3212

1098-4275

Mark L. Hudak, Rosemarie C. Tan, Daniel A.C. Frattarelli, Jeffrey L. Galinkin, Thomas P. Green, Kathleen Neville, Ian M. Paul, John N. van den Anker, Mary A. Hegenbarth, Matthew Knight, Robert E. Shaddy, Wayne R. Snodgrass, John Alexander, Nancy C. Chescheir, Janet D. Cragan, Michael J. Rieder, Adelaide S. Robb, Hari Cheryl Sachs, Anne Zajicek, George P. Giacoia, Mark Del Monte, Raymond J. Koteras, Lu Ann Papile, Jill E. Baley, Vinod K. Bhutani, Waldemar A. Carlo, James J. Cummings, Praveen Kumar, Richard A. Polin, Kasper S. Wang, Kristi L. Watterberg, David H. Adamkin, Wanda D. Barfield, George A. Macones, Ann L. Jefferies, Rosalie O. Mainous, Tonse N.K. Raju, William H. Barth, Jim Couto,

Electrolyte and hormonal disorders

Maternal use of certain drugs during pregnancy can result in transient neonatal signs consistent with withdrawal or acute toxicity or cause sustained signs consistent with a lasting drug effect. In addition, hospitalized infants who are treated with opioids or benzodiazepines to provide analgesia or sedation may be at risk for manifesting signs of withdrawal. This statement updates information about the clinical presentation of infants exposed to intrauterine drugs and the therapeutic options for treatment of withdrawal and is expanded to include evidence-based approaches to the management of the hospitalized infant who requires weaning from analgesics or sedatives.